Cargando…
Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study
Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230591/ https://www.ncbi.nlm.nih.gov/pubmed/32326347 http://dx.doi.org/10.3390/nu12041159 |
_version_ | 1783534990259126272 |
---|---|
author | Lewis, Erin D. Antony, Joseph M. Crowley, David C. Piano, Amanda Bhardwaj, Renu Tompkins, Thomas A. Evans, Malkanthi |
author_facet | Lewis, Erin D. Antony, Joseph M. Crowley, David C. Piano, Amanda Bhardwaj, Renu Tompkins, Thomas A. Evans, Malkanthi |
author_sort | Lewis, Erin D. |
collection | PubMed |
description | Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum) in reducing the GI and psychological symptoms of IBS was evaluated in 251 adults with either constipation (IBS-C), diarrhea (IBS-D), or mixed-pattern (IBS-M). Following a 2-week run-in period, participants were randomized to one of three interventions: L. paracasei (n = 84), B. longum (n = 83) or placebo (n = 81). IBS symptoms, stool frequency and consistency and quality of life were assessed by questionnaires. The differences from baseline in the severity of IBS symptoms at 4 and 8 weeks were similar between groups. Participants in this study were classified, after randomization, into subtypes according to Rome III. Within the L. paracasei group, complete spontaneous and spontaneous bowel movement frequency increased in participants with IBS-C (n = 10) after 8 weeks of supplementation (both p < 0.05) and decreased in participants with IBS-D (n = 10, p = 0.013). Both L. paracasei and B. longum supplementation improved the quality of life in emotional well-being and social functioning compared with baseline (all p < 0.05). In conclusion, L. paracasei and B. longum may reduce GI symptom severity and improve the psychological well-being of individuals with certain IBS subtypes. |
format | Online Article Text |
id | pubmed-7230591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72305912020-05-22 Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study Lewis, Erin D. Antony, Joseph M. Crowley, David C. Piano, Amanda Bhardwaj, Renu Tompkins, Thomas A. Evans, Malkanthi Nutrients Article Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum) in reducing the GI and psychological symptoms of IBS was evaluated in 251 adults with either constipation (IBS-C), diarrhea (IBS-D), or mixed-pattern (IBS-M). Following a 2-week run-in period, participants were randomized to one of three interventions: L. paracasei (n = 84), B. longum (n = 83) or placebo (n = 81). IBS symptoms, stool frequency and consistency and quality of life were assessed by questionnaires. The differences from baseline in the severity of IBS symptoms at 4 and 8 weeks were similar between groups. Participants in this study were classified, after randomization, into subtypes according to Rome III. Within the L. paracasei group, complete spontaneous and spontaneous bowel movement frequency increased in participants with IBS-C (n = 10) after 8 weeks of supplementation (both p < 0.05) and decreased in participants with IBS-D (n = 10, p = 0.013). Both L. paracasei and B. longum supplementation improved the quality of life in emotional well-being and social functioning compared with baseline (all p < 0.05). In conclusion, L. paracasei and B. longum may reduce GI symptom severity and improve the psychological well-being of individuals with certain IBS subtypes. MDPI 2020-04-21 /pmc/articles/PMC7230591/ /pubmed/32326347 http://dx.doi.org/10.3390/nu12041159 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lewis, Erin D. Antony, Joseph M. Crowley, David C. Piano, Amanda Bhardwaj, Renu Tompkins, Thomas A. Evans, Malkanthi Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study |
title | Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study |
title_full | Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study |
title_fullStr | Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study |
title_full_unstemmed | Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study |
title_short | Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study |
title_sort | efficacy of lactobacillus paracasei ha-196 and bifidobacterium longum r0175 in alleviating symptoms of irritable bowel syndrome (ibs): a randomized, placebo-controlled study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230591/ https://www.ncbi.nlm.nih.gov/pubmed/32326347 http://dx.doi.org/10.3390/nu12041159 |
work_keys_str_mv | AT lewiserind efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy AT antonyjosephm efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy AT crowleydavidc efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy AT pianoamanda efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy AT bhardwajrenu efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy AT tompkinsthomasa efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy AT evansmalkanthi efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy |